HomeProductsBioactive CompoundsMetabolic EnzymesCarbonic AnhydraseTaselisib
Chemical structure of CAS 1282512-48-4

Taselisib

CAS No.1282512-48-4
MDL No.MFCD26142641
MFC24H28N8O2
MW460.50
InChI KeyBEUQXVWXFDOSAQ-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1282512-48-4
Product NameTaselisib

Biological Targets

PIK3R1·PIK3CB·PIK3CG·PIK3CA·PIK3R2·

Associated Conditions

lung cancer·squamous cell lung carcinoma·non-Hodgkins lymphoma·breast cancer·triple-negative breast cancer·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

Gynecologic oncology • Vol. 135, Issue 2 • 2014
PMID: 25172762PMC: PMC4270135DOI: 10.1016/j.ygyno.2014.08.024

Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.

Journal of medicinal chemistry • Vol. 56, Issue 11 • 2013
PMID: 23662903DOI: 10.1021/jm4003632

Documentation